

LICENSE AGREEMENT

Vericel Corporation – Innovative Cellular Therapeutics Co.,Ltd.



GENERAL INFORMATION

Deal date:	May 2017	Orphan status:	No
		Exclusivity:	Yes
Type of agreement:	Licensing – product / compound	Type of collaboration:	Co-development, Co-marketing
Licensor:	Vericel Corporation	Licensee:	Innovative Cellular Therapeutics Co, Ltd.

Agreement description:

Vericel Corporation and Innovative Cellular Therapeutics entered in to an agreement for development, manufacturing and commercialization of the Vericel product portfolio: Carticel®, MACI®, Ixmyelocel-T, and Epicel® in Greater China, South Korea, Singapore, and other countries in the region.

Territory including
China (Mainland)
South Korea
Singapore

Sources:
Contract [Download PDF](#)
Press release [Download PDF](#) [View in Browser](#)

COMPOUND INFORMATION

Compound Name: Carticel®, MACI®, Ixmyelocel-T and Epicel®

MILESTONES & ROYALTIES

Deal size: USD 14.00 million

Upfront payments: USD 6.00 million

Upfront remarks: Vericel received an upfront payment of USD 6.0 million.

Total milestone amount: USD 8.00 million

Milestone remarks: Vericel received approximately USD 8.0 million in development and commercial milestones.